Embryo Developmental Capacity After Egg Banking in an Ovum Donation Program

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00977821

Enrollment

625

Registered

2009-09-16

Start date

2009-09-30

Completion date

2014-05-31

Last updated

2015-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Brief summary

For an efficient egg banking system, an equally efficient cryopreservation strategy that ensures the viability of the oocytes is required. Very recently, improved and new methods are yielding satisfactory results. In particular, vitrification is providing excellent results for both survival and clinical outcomes. However, to evaluate the over all out come there are other parameters to be considered. In this sense, capacity development of embryos generated after oocyte vitrification is a major factor when assessing the viability of vitrified oocytes. Accordingly, the evaluation of the capacity of vitrified oocytes to reach the blastocyst stage will be highly valuable to fully assess the effectiveness of the egg banking and its contribution to ovum donation programs. The aim of this study is to evaluate the developmental capacity of vitrified oocytes by their ability to reach the blastocyst stage. The study includes oocyte donation cycles conducted with vitrified versus fresh oocytes.

Interventions

OTHERIVF

OTHEROocyte Vitrification

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 35 Years

Healthy volunteers

Yes

Inclusion criteria

* 18-35 year old * Normal response (8-15 follicles) to long protocol of ovarian stimulation with hCG * Donors with normal menstrual cycles (21-35 day duration) * Donors with BMI between 18-25 Kg/m2

Exclusion criteria

* Donors with two or more previous miscarriages * Polycystic ovary syndrome * Donors with antecedents of poor embrionary quality not attributed to masculine factor * Donors with drop of estradiol of more than 10% or estradiol plateau. * Donors with a high response\>20 oocytes and or levels above 3000pg/ml of estradiol the day of the administration of chorionic gonadotrophin (hCG)

Design outcomes

Primary

Measure	Time frame
Mean outcome measures will be survival, fertilization and blastocyst rates and clinical outcome.	10 months

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026